Gilead Sciences, Inc. (NASDAQ:GILD) Position Raised by ARGI Investment Services LLC

ARGI Investment Services LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,268 shares of the biopharmaceutical company’s stock after acquiring an additional 4,738 shares during the period. ARGI Investment Services LLC’s holdings in Gilead Sciences were worth $5,257,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of GILD. Vanguard Group Inc. grew its holdings in Gilead Sciences by 0.7% during the 2nd quarter. Vanguard Group Inc. now owns 105,017,942 shares of the biopharmaceutical company’s stock worth $7,231,535,000 after acquiring an additional 754,213 shares during the last quarter. State Street Corp grew its holdings in shares of Gilead Sciences by 1.6% in the second quarter. State Street Corp now owns 54,299,659 shares of the biopharmaceutical company’s stock worth $3,739,075,000 after purchasing an additional 829,887 shares during the last quarter. Dodge & Cox raised its position in shares of Gilead Sciences by 56.9% in the 2nd quarter. Dodge & Cox now owns 28,961,844 shares of the biopharmaceutical company’s stock worth $1,994,313,000 after purchasing an additional 10,499,694 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Gilead Sciences by 6.0% during the 2nd quarter. Geode Capital Management LLC now owns 21,915,321 shares of the biopharmaceutical company’s stock valued at $1,505,514,000 after acquiring an additional 1,244,015 shares during the period. Finally, Morgan Stanley raised its holdings in shares of Gilead Sciences by 18.3% during the 2nd quarter. Morgan Stanley now owns 10,989,872 shares of the biopharmaceutical company’s stock worth $756,765,000 after acquiring an additional 1,702,366 shares in the last quarter. 78.67% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have recently weighed in on GILD. Evercore ISI restated a “buy” rating on shares of Gilead Sciences in a research report on Sunday, October 31st. BMO Capital Markets reiterated a “buy” rating on shares of Gilead Sciences in a research note on Wednesday, December 15th. The Goldman Sachs Group initiated coverage on shares of Gilead Sciences in a research report on Monday, December 6th. They issued a “neutral” rating and a $80.00 price target on the stock. Morgan Stanley cut shares of Gilead Sciences from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $84.00 to $74.00 in a research note on Thursday, January 6th. Finally, Wells Fargo & Company began coverage on shares of Gilead Sciences in a research report on Wednesday, December 8th. They issued an “equal weight” rating and a $72.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Buy” and an average target price of $78.75.

Shares of GILD stock traded down $0.40 during midday trading on Friday, hitting $71.48. 401,146 shares of the company were exchanged, compared to its average volume of 6,775,222. The firm’s 50 day moving average price is $70.39 and its two-hundred day moving average price is $69.73. The firm has a market capitalization of $89.66 billion, a P/E ratio of 12.25, a PEG ratio of 0.71 and a beta of 0.34. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.20 and a current ratio of 1.37. Gilead Sciences, Inc. has a 52 week low of $61.39 and a 52 week high of $74.12.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 28th. The biopharmaceutical company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.93. The firm had revenue of $7.42 billion during the quarter, compared to analyst estimates of $6.31 billion. Gilead Sciences had a net margin of 26.91% and a return on equity of 56.59%. The company’s quarterly revenue was up 12.8% on a year-over-year basis. During the same quarter last year, the business earned $2.11 earnings per share. Analysts expect that Gilead Sciences, Inc. will post 8.06 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Thursday, December 30th. Investors of record on Wednesday, December 15th were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.97%. The ex-dividend date of this dividend was Tuesday, December 14th. Gilead Sciences’s dividend payout ratio is currently 48.46%.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Recommended Story: Diversification in Investing

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.